AstraZeneca’s COVID-19 vaccine: benefits and risks in context

This risk assessment addresses the benefits of reduced hospitalisation, the increased risk of venous thromboembolism in different age groups, and the recommendation to administer the second dose within 4-12 weeks and areas of uncertainty with the data.

Source:

European Medicines Agency